All comparisons
Each page compares two tools across 12 dimensions — price, eligibility, availability, source base, reasoning transparency, benchmarks, and compliance posture — and says plainly which one to pick for which job.
OpenEvidence vs UpToDate
OpenEvidence is a free literature search engine; UpToDate is a paid, expert-authored reference. Choose OpenEvidence for fast questions about recent evidence if you hold a U.S. NPI. Choose UpToDate for curated depth and clinical governance, at $579/yr or $699/yr for Pro Plus with Expert AI. Neither shows its reasoning.
UpToDate vs DynaMedex
UpToDate wins on narrative depth and institutional trust; DynaMedex wins on drug data and access breadth, bundling Micromedex and reaching clinicians free through hospitals, universities, and public libraries. UpToDate publishes individual pricing from $579/yr; EBSCO publishes none for DynaMedex, so access is effectively institution-dependent.
UpToDate vs ClinicalKey AI
A corpus-and-integration decision rather than a capability one. UpToDate wins on clinician familiarity, editorial depth, and published pricing from $579/yr. ClinicalKey AI wins on daily-refreshed Elsevier full text, real-time citation validation, SMART on FHIR EHR embedding, and CME or MOC credit earned in workflow.
UpToDate vs AMBOSS
Different readers. AMBOSS is built for students and trainees, pairing a reference library with an adaptive question bank at $149–$259/yr. UpToDate is built for practising clinicians who need editorial depth and citability, from $579/yr. If you are studying for boards and also want point-of-care reference, AMBOSS is the better single purchase.
UpToDate vs BMJ Best Practice
For NHS staff in England, Scotland, or Wales this is not a close call: BMJ Best Practice is free through national funding, while UpToDate costs from $579/yr. Outside those schemes, UpToDate has greater depth and wider international familiarity. Many UK clinicians already hold BMJ access they have never used.
OpenEvidence vs ClinicalKey AI
OpenEvidence is free, individual, and U.S.-gated; ClinicalKey AI is institutional, sales-led, and embedded in the EHR. An individual U.S. clinician can start OpenEvidence today at no cost. A health system wanting validated citations, SMART on FHIR SSO, and in-workflow CME needs ClinicalKey AI.
OpenEvidence vs DynaMedex
OpenEvidence is free literature synthesis for verified U.S. clinicians; DynaMedex is a curated reference bundling Micromedex drug data, reached through institutional or library licensing. Many clinicians can get DynaMed free through a hospital, university, or public library — often the cheapest route if you lack a U.S. NPI.
OpenEvidence vs Doximity Ask
Both are free and both require U.S. clinician verification, so this is a convenience decision. OpenEvidence is the stronger dedicated evidence tool, grounded in peer-reviewed literature. Doximity Ask wins if you already live in Doximity daily and want cited answers without adding another app.
OpenEvidence vs BMJ Best Practice
For a UK clinician this resolves quickly: OpenEvidence withdrew from the UK in April 2026, while BMJ Best Practice is free to NHS staff in England, Scotland, and Wales through national funding. Where both are available, OpenEvidence suits recent-literature questions and BMJ Best Practice suits UK pathway wording.
ClinicalKey AI vs DynaMedex
Both are institutional purchases with no published individual pricing, so this is a procurement comparison. ClinicalKey AI offers a daily-refreshed Elsevier corpus, real-time citation validation, SMART on FHIR SSO, and in-workflow CME. DynaMedex offers Micromedex drug data and unusually broad free access through libraries and societies.
EvidenceMD vs the field
One finding holds across all ten comparisons: every tool above returns a cited answer without showing how it reached it. Sensible for looking something up, poor for a diagnostic question — where the reasoning is the part you need to check.
| Capability | EvidenceMD | The other ten tools |
|---|---|---|
| Shows its reasoning | Yes — streamed chain-of-thought, up to 64,000 thinking tokens, auditable afterwards | No — a cited answer with no reasoning trace to inspect |
| Model approach | Specialty-trained: fine-tuned across 40+ medical specialties | A curated corpus, or a general model layered over one |
| Published accuracy benchmarks | Yes — state of the art on HealthBench Hard at 54.6% | None published by the vendor |
| Output format | Structured artifacts: ranked differential, assessment & plan, lab trend charts, note | Prose answer with citations attached |
| Cost to start | Free, worldwide | Free but credential-gated, $149–$699/yr, or an institutional quote |
| Verification required | None | A U.S. NPI, a paid subscription, or institutional login |
| Availability | Worldwide, in 30 languages | U.S.-gated, NHS-gated, institution-gated, or English-only |
| Developer API | Yes — OpenAI-compatible | No public self-serve API |
What one encounter produces
- Ranked differentialEach diagnosis carries its own reasoning and peer-reviewed citations, ordered by likelihood rather than listed flat.
- Assessment & planProblem-based, built from the same encounter rather than re-entered, so the plan traces back to the findings.
- Reasoning traceUp to 64,000 thinking tokens streamed step by step and auditable afterwards for review or teaching.
- Lab trend visualisationResults interpreted over time with trend charts and clinical significance flagging, not just current values.
- Clinical noteGenerated from the encounter with documentation integrity support, so the note reflects the reasoning.
- Cited clinical Q&AFollow-up questions answered in the context of this patient, with sources attached to each claim.
The ten comparisons above deliberately exclude EvidenceMD pairings, so they stay useful whichever tool you choose. For direct head-to-heads, see the dedicated guides.
Go deeper
- OpenEvidence vs UpToDate vs ClinicalKey AI vs EvidenceMD (2026)The full six-tool matrix across 13 dimensions, with one-line verdicts by clinical job.
- Clinical AI tools pricing & access (2026)What each of 9 tools costs and who is actually eligible, with a region-by-region availability table.
- Best clinical decision support tools (2026), rankedScored across five dimensions and ranked by the decision each tool supports.